Sugi Predict

Sugi Predict / Compounds / SCHEMBL843323

SCHEMBL843323

SCHEMBL843323

CC(C)(F)CNC(=O)OC(C)(C)C

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TDP1 Q9NUW8 1/20 0.48
▸ MEN1 O00255 2/20 0.46
▸ KMT2A Q03164 2/20 0.46
▸ GAA P10253 1/20 0.46
▸ MAOA P21397 1/20 0.42
▸ MAOB P27338 1/20 0.42
▸ APLNR P35414 1/20 0.41
▸ CA1 P00915 4/20 0.40
▸ CA2 P00918 4/20 0.40
▸ CA12 O43570 4/20 0.40
▸ CA9 Q16790 2/20 0.40
▸ EPHX1 P07099 1/20 0.40
▸ CA7 P43166 2/20 0.39
▸ ALDH1A1 P00352 1/20 0.38
▸ TSHR P16473 1/20 0.38
▸ LMNA P02545 2/20 0.37
▸ POLB P06746 1/20 0.37
▸ KDM4E B2RXH2 1/20 0.37
▸ CA14 Q9ULX7 3/20 0.37
▸ CTSS P25774 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4202727 0.87 TDP1 (0.48) TDP1MEN1KMT2AGAAMAOA
SCHEMBL12698678 0.87 TDP1 (0.48) TDP1MEN1KMT2AGAAMAOA
SCHEMBL28760650 0.83 TDP1 (0.50) TDP1MEN1KMT2AGAAMAOA
SCHEMBL3229252 0.83 TDP1 (0.46) TDP1MEN1KMT2AGAAMAOA
SCHEMBL21065336 0.82 TDP1 (0.52) TDP1MEN1KMT2AGAAMAOA
SCHEMBL842921 0.82 TDP1 (0.52) TDP1MEN1KMT2AGAAMAOA
SCHEMBL255203 0.82 TDP1 (0.52) TDP1MEN1KMT2AGAAMAOA
SCHEMBL13771768 0.82 TDP1 (0.44) TDP1MEN1KMT2AGAAMAOA
SCHEMBL19040100 0.82 TDP1 (0.44) TDP1MEN1KMT2AGAAMAOA
SCHEMBL14744344 0.82 TDP1 (0.44) TDP1MEN1KMT2AGAAMAOA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114845778-A Dihydrocyclopentaisoquinoline sulfonamide derivative compound UCB生物制药有限责任公司 2022-08-02 — — CN disclosed
WO-2020025517-A1 TLR7/8 ANTAGONISTS AND USES THEREOF MERCK PATENT GMBH (DE) 2020-02-06 — — WO disclosed
US-9949975-B2 Inhibitors of beta-secretase VITAE PHARMACEUTICALS, INC. (US) 2018-04-24 — — US disclosed
US-9949975-B2 Inhibitors of beta-secretase VITAE PHARMACEUTICALS, INC. (US) 2018-04-24 — — US disclosed
US-20170196867-A1 INHIBITORS OF BETA-SECRETASE VITAE PHARMACEUTICALS, INC. (US) 2017-07-13 — — US disclosed
US-20170196867-A1 INHIBITORS OF BETA-SECRETASE VITAE PHARMACEUTICALS, INC. (US) 2017-07-13 — — US disclosed
US-9526727-B2 Inhibitors of beta-secretase VITAE PHARMACEUTICAL, INC. (US) 2016-12-27 — — US disclosed
US-9526727-B2 Inhibitors of beta-secretase VITAE PHARMACEUTICAL, INC. (US) 2016-12-27 — — US disclosed
EP-2822930-B1 INHIBITORS OF BETA-SECRETASE BOEHRINGER INGELHEIM INT (DE) 2016-01-20 — — EP disclosed
US-20150239849-A1 INHIBITORS OF BETA-SECRETASE DOW AGROSCIENCES LLC 2015-08-27 — — US disclosed
US-7897609-B2 Aryl substituted imidazonaphthyridines 3M INNOVATIVE PROPERTIES COMPANY (US) 2011-03-01 — — US disclosed
US-20090253695-A1 Hydroxyalkyl Substituted Imidazonaphthyridines COLEY PHARMACEUTICAL GROUP, INC, (US) 2009-10-08 — — US disclosed
US-20090030031-A1 Method of Preferentially Inducing the Biosynthesis of Interferon COLEY PHARMACEUTICAL GROUP, INC. (US) 2009-01-29 — — US disclosed
US-20090023720-A1 2-Amino 1H-Imidazo Ring Systems and Methods 3M INNOVATIVE PROPERTIES COMPANY 2009-01-22 — — US disclosed
EP-1851220-A2 HYDROXYALKYL SUBSTITUTED IMIDAZONAPHTHYRIDINES 3M Innovative Properties Company (US) 2007-11-07 — — EP disclosed
EP-1850849-A2 METHOD OF PREFERENTIALLY INDUCING THE BIOSYNTHESIS OF INTERFERON Coley Pharmaceutical Group, Inc. (US) 2007-11-07 — — EP disclosed
US-20070219228-A1 Aryl substituted imidazonaphthyridines 3M INNOVATIVE PROPERTIES COMPANY 2007-09-20 — — US disclosed
WO-2006091647-A2 METHOD OF PREFERENTIALLY INDUCING THE BIOSYNTHESIS OF INTERFERON COLEY PHARMACEUTICAL GROUP, INC. (US) 2006-08-31 — — WO disclosed
WO-2006091568-A2 HYDROXYALKYL SUBSTITUTED IMIDAZONAPHTHYRIDINES COLEY PHARMACEUTICAL GROUP, INC. (US) 2006-08-31 — — WO disclosed
WO-2006038923-A2 ARYL SUBSTITUTED IMIDAZONAPHTHYRIDINES 3M INNOVATIVE PROPERTIES COMPANY (US) 2006-04-13 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090030031-A1 Method of Preferentially Inducing the Biosynthesis of Interferon IFNG, IFNAR1, EIF2AK2 TDP1 3223/4885MEN1 4113/4885KMT2A 2737/4885
US-20090253695-A1 Hydroxyalkyl Substituted Imidazonaphthyridines IFNG, IFNAR1, IRF3 TDP1 1730/4885MEN1 4587/4885KMT2A 2533/4885
US-20150239849-A1 INHIBITORS OF BETA-SECRETASE BACE1, BACE2, APH1B TDP1 483/4885MEN1 3463/4885KMT2A 3275/4885
US-20070219228-A1 Aryl substituted imidazonaphthyridines IL2, IRF3, EIF2AK2 TDP1 3959/4885MEN1 4622/4885KMT2A 3772/4885
US-20090023720-A1 2-Amino 1H-Imidazo Ring Systems and Methods IL2, IL2RA, IL4I1 TDP1 3141/4885MEN1 3048/4885KMT2A 1860/4885
US-20170196867-A1 INHIBITORS OF BETA-SECRETASE BACE1, BACE2, APH1B TDP1 483/4885MEN1 3463/4885KMT2A 3275/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.